ATE318258T1 - Benzamidformulierung mit histon-deacetylase- inhibitoraktivität - Google Patents

Benzamidformulierung mit histon-deacetylase- inhibitoraktivität

Info

Publication number
ATE318258T1
ATE318258T1 AT00956496T AT00956496T ATE318258T1 AT E318258 T1 ATE318258 T1 AT E318258T1 AT 00956496 T AT00956496 T AT 00956496T AT 00956496 T AT00956496 T AT 00956496T AT E318258 T1 ATE318258 T1 AT E318258T1
Authority
AT
Austria
Prior art keywords
histone deacetylase
deacetylase inhibitor
inhibitor activity
benzamide
formulation
Prior art date
Application number
AT00956496T
Other languages
English (en)
Inventor
Masahiko Ishibashi
Masahiro Sakabe
Ikuo Sakai
Tsuneji Suzuki
Tomoyuki Ando
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Application granted granted Critical
Publication of ATE318258T1 publication Critical patent/ATE318258T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00956496T 1999-08-30 2000-08-29 Benzamidformulierung mit histon-deacetylase- inhibitoraktivität ATE318258T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP24244499A JP2001081031A (ja) 1999-08-30 1999-08-30 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤

Publications (1)

Publication Number Publication Date
ATE318258T1 true ATE318258T1 (de) 2006-03-15

Family

ID=17089193

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00956496T ATE318258T1 (de) 1999-08-30 2000-08-29 Benzamidformulierung mit histon-deacetylase- inhibitoraktivität

Country Status (32)

Country Link
US (1) US6638530B1 (de)
EP (1) EP1208086B1 (de)
JP (2) JP2001081031A (de)
KR (1) KR100712640B1 (de)
CN (1) CN1147472C (de)
AR (1) AR025434A1 (de)
AT (1) ATE318258T1 (de)
AU (1) AU773617B2 (de)
BG (1) BG65544B1 (de)
BR (1) BR0013648A (de)
CA (1) CA2382886C (de)
CZ (1) CZ301737B6 (de)
DE (1) DE60026144T2 (de)
DK (1) DK1208086T3 (de)
EE (1) EE05063B1 (de)
ES (1) ES2259289T3 (de)
HK (1) HK1046277B (de)
HR (1) HRP20020182B1 (de)
HU (1) HUP0203330A3 (de)
IL (2) IL148357A0 (de)
MX (1) MXPA02002090A (de)
NO (1) NO322532B1 (de)
NZ (1) NZ517520A (de)
PL (1) PL201274B1 (de)
PT (1) PT1208086E (de)
RU (1) RU2260428C2 (de)
SI (1) SI1208086T1 (de)
SK (1) SK287252B6 (de)
TW (1) TWI268778B (de)
UA (1) UA72541C2 (de)
WO (1) WO2001016106A1 (de)
ZA (1) ZA200201424B (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658938B2 (en) * 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
US8119159B2 (en) * 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
EP1374855A1 (de) * 2001-03-30 2004-01-02 Takeda Chemical Industries, Ltd. Medizinische lösungen
EP1429765A2 (de) 2001-09-14 2004-06-23 Methylgene, Inc. Histone deacetylase-hemmer
US7868204B2 (en) 2001-09-14 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
US6897220B2 (en) 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
AU2006252047B2 (en) * 2001-09-14 2010-02-11 Methylgene Inc. Inhibitors of histone deacetylase
US6706686B2 (en) 2001-09-27 2004-03-16 The Regents Of The University Of Colorado Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
EP1443928B1 (de) 2001-10-16 2011-07-27 Sloan-Kettering Institute For Cancer Research Behandlung von neurodegenerativen erkrankungen und krebs im gehirn
JPWO2003070691A1 (ja) * 2002-02-21 2005-06-09 財団法人大阪産業振興機構 Ｎ−ヒドロキシカルボキサミド誘導体
US7456219B2 (en) 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
US7148257B2 (en) 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
WO2003075839A2 (en) 2002-03-04 2003-09-18 Aton Pharma, Inc. Methods of inducing terminal differentiation
ATE458047T1 (de) 2002-03-07 2010-03-15 Univ Delaware Verfahren zur verstärkung der oligonucleotid- vermittelten nucleinsäuresequenzänderung unter verwendung von zusammensetzungen mit einem hydroxyharnstoff
GB0209715D0 (en) * 2002-04-27 2002-06-05 Astrazeneca Ab Chemical compounds
DE10233412A1 (de) * 2002-07-23 2004-02-12 4Sc Ag Neue Verbindungen als Histondeacetylase-Inhibitoren
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
GB0226855D0 (en) * 2002-11-18 2002-12-24 Queen Mary & Westfield College Histone deacetylase inhibitors
US7244751B2 (en) * 2003-02-14 2007-07-17 Shenzhen Chipscreen Biosciences Ltd. Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity
CA2518318A1 (en) 2003-03-17 2004-09-30 Takeda San Diego, Inc. Histone deacetylase inhibitors
CN100455564C (zh) * 2003-09-12 2009-01-28 深圳微芯生物科技有限责任公司 组蛋白去乙酰化酶抑制剂及其药用制剂的制备和应用
KR101153335B1 (ko) * 2003-09-24 2012-07-05 메틸진 인코포레이티드 히스톤 데아세틸라제의 억제제
CN101445469B (zh) * 2003-09-24 2013-02-13 梅特希尔基因公司 组蛋白脱乙酰基酶抑制剂
DK1696898T3 (en) * 2003-12-02 2016-02-22 Univ Ohio State Res Found ZN2 + -CHELATING DESIGN-BASED SHORT-CHAIN FAT ACIDS AS AN UNKNOWN CLASS OF HISTONDEACETYLASE INHIBITORS
EP1697538A1 (de) * 2003-12-18 2006-09-06 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Verfahren zur identifizierung von histondeacetylase-inhibitoren
US7253204B2 (en) 2004-03-26 2007-08-07 Methylgene Inc. Inhibitors of histone deacetylase
JP2008524246A (ja) 2004-12-16 2008-07-10 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
US20100087328A1 (en) * 2005-03-01 2010-04-08 The Regents Of The University Of Michigan Brm expression and related diagnostics
WO2006094068A2 (en) * 2005-03-01 2006-09-08 The Regents Of The University Of Michigan Hdac inhibitors that promote brm expression and brm related diagnostics
US7642253B2 (en) 2005-05-11 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
TWI365068B (en) 2005-05-20 2012-06-01 Merck Sharp & Dohme Formulations of suberoylanilide hydroxamic acid and methods for producing same
EA200800321A1 (ru) 2005-07-14 2008-06-30 Такеда Сан Диего, Инк. Ингибиторы гистондеацетилазы
US20100152188A1 (en) * 2005-08-05 2010-06-17 Akella Satya Surya Visweswara Srinivas Novel Heterocyclic Compounds
KR101495611B1 (ko) 2006-04-07 2015-02-25 메틸진 인코포레이티드 히스톤 데아세틸라아제의 억제제
KR101191322B1 (ko) * 2006-04-07 2012-10-16 메리온 리서치 Ⅲ 리미티드 증진제를 함유하는 고형 경구용 투여 제형
EP2040731A4 (de) * 2006-06-09 2010-05-19 Merrion Res Iii Ltd Feste orale dosierform mit einem verstärkungsmittel
EP2135620A4 (de) 2007-03-28 2010-12-29 Santen Pharmaceutical Co Ltd Mittel gegen okuläre hypotonie mit einer verbindung zur histondeacetylasehemmung als wirkstoff
US20110044952A1 (en) * 2007-11-27 2011-02-24 Ottawa Health Research Institute Amplification of cancer-specific oncolytic viral infection by histone deacetylase inhibitors
US20110182888A1 (en) * 2008-04-08 2011-07-28 Peter Ordentlich Administration of an Inhibitor of HDAC, an Inhibitor of HER-2, and a Selective Estrogen Receptor Modulator
CN107096012A (zh) * 2008-05-07 2017-08-29 诺和诺德股份有限公司 肽的组合物及其制备方法
EP2285376A4 (de) * 2008-05-16 2011-07-20 Chipscreen Biosciences Ltd 6-aminonicotinamidderivate als wirksame und selektive histondeacetylasehemmer
WO2010011700A2 (en) 2008-07-23 2010-01-28 The Brigham And Women's Hospital, Inc. Treatment of cancers characterized by chromosomal rearrangement of the nut gene
US20100215743A1 (en) * 2009-02-25 2010-08-26 Leonard Thomas W Composition and drug delivery of bisphosphonates
WO2011120033A1 (en) 2010-03-26 2011-09-29 Merrion Research Iii Limited Pharmaceutical compositions of selective factor xa inhibitors for oral administration
EP2661273A4 (de) 2011-01-07 2014-06-04 Merrion Res Iii Ltd Pharmazeutische zusammensetzungen aus eisen zur oralen verabreichung
CN103172540B (zh) * 2013-03-18 2015-07-01 潍坊博创国际生物医药研究院 苯甘氨酸类组蛋白去乙酰酶抑制剂及其制备方法和应用
WO2015051035A1 (en) 2013-10-01 2015-04-09 The J. David Gladstone Institutes Compositions, systems and methods for gene expression noise drug screening and uses thereof
US10265384B2 (en) 2015-01-29 2019-04-23 Novo Nordisk A/S Tablets comprising GLP-1 agonist and enteric coating
PL3954690T3 (pl) 2015-07-02 2023-08-14 Acerta Pharma B.V. Postacie stałe i formulacje (s)-4-(8-amino-3-(1-(but-2-ynoilo)pirolidyn-2-ylo)imidazo[1,5-a]-pirazyn-1-ylo)-n-(pirydyn-2-ylo)benzamidu
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
MX2019000342A (es) * 2016-07-08 2019-09-04 Ranedis Pharmaceuticals Llc Composiciones y metodos para tratar y/o prevenir enfermedades de almacenamiento lisosomal y otras enfermedades metabolicas monogeneticas.
WO2018222572A1 (en) * 2017-06-01 2018-12-06 Warner Babcock Institute For Green Chemistry, Llc Non-covalent derivatives and methods of treatment
US20180353446A1 (en) * 2017-06-07 2018-12-13 Ranedis Pharmaceuticals, Llc Compositions and methods of treating and/or preventing cancer
EP3960240B1 (de) 2019-04-25 2024-03-27 Fuji Pharma Co., Ltd. Pharmazeutisches präparat und verfahren zur herstellung davon
CN112294810B (zh) * 2019-07-29 2024-03-01 深圳微芯生物科技股份有限公司 含有西达本胺和表面活性剂的药物组合物
TWI890738B (zh) 2020-10-28 2025-07-21 日商基諾製藥股份有限公司 用於預防或治療病毒性陰道周邊部疾病的藥物組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ513800A (en) * 1996-08-12 2001-09-28 Welfide Corp Treatment of diseases using Rho kinase inhibitors
US6174905B1 (en) * 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
JP3354090B2 (ja) * 1996-09-30 2002-12-09 シエーリング アクチエンゲゼルシャフト 分化誘導剤
DE69835594T2 (de) * 1997-02-17 2007-08-16 Altana Pharma Ag Zusammensetzungen zur behandlung von irds oder ards die 3-(cyclopropylmethoxy)-n-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy) benzamid und lungensurfactant enthalten
JP4405602B2 (ja) * 1998-04-16 2010-01-27 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト ヒストン脱アセチル化酵素阻害剤
JP2000256194A (ja) * 1999-01-06 2000-09-19 Mitsui Chemicals Inc 核内レセプタ作動薬およびその効果増強剤
JP2001064177A (ja) * 1999-08-16 2001-03-13 Schering Ag ベンズアミド誘導体を有効成分とする製剤

Also Published As

Publication number Publication date
HRP20020182B1 (en) 2007-08-31
SK287252B6 (sk) 2010-04-07
CZ2002724A3 (cs) 2002-07-17
TWI268778B (en) 2006-12-21
HUP0203330A3 (en) 2004-03-01
RU2260428C2 (ru) 2005-09-20
JP2001081031A (ja) 2001-03-27
BR0013648A (pt) 2002-05-07
MXPA02002090A (es) 2003-08-20
NO20020952L (no) 2002-03-20
PL201274B1 (pl) 2009-03-31
CA2382886A1 (en) 2001-03-08
BG65544B1 (bg) 2008-11-28
BG106439A (en) 2002-11-29
HUP0203330A2 (hu) 2003-02-28
JP2003508386A (ja) 2003-03-04
ZA200201424B (en) 2002-11-27
DK1208086T3 (da) 2006-06-19
HRP20020182A2 (en) 2004-02-29
NO20020952D0 (no) 2002-02-27
IL148357A (en) 2006-12-10
US6638530B1 (en) 2003-10-28
AU6841600A (en) 2001-03-26
NZ517520A (en) 2003-05-30
AR025434A1 (es) 2002-11-27
EP1208086B1 (de) 2006-02-22
PL353063A1 (en) 2003-10-06
AU773617B2 (en) 2004-05-27
KR20020023424A (ko) 2002-03-28
CZ301737B6 (cs) 2010-06-09
EE200200097A (et) 2003-04-15
CN1371366A (zh) 2002-09-25
ES2259289T3 (es) 2006-10-01
EP1208086A1 (de) 2002-05-29
DE60026144D1 (de) 2006-04-27
HK1046277B (zh) 2004-11-26
UA72541C2 (en) 2005-03-15
CA2382886C (en) 2009-06-09
PT1208086E (pt) 2006-07-31
CN1147472C (zh) 2004-04-28
DE60026144T2 (de) 2006-11-16
EE05063B1 (et) 2008-08-15
IL148357A0 (en) 2002-09-12
KR100712640B1 (ko) 2007-05-02
NO322532B1 (no) 2006-10-23
WO2001016106A1 (en) 2001-03-08
SI1208086T1 (sl) 2006-08-31
SK2612002A3 (en) 2002-09-10
HK1046277A1 (en) 2003-01-03

Similar Documents

Publication Publication Date Title
ATE318258T1 (de) Benzamidformulierung mit histon-deacetylase- inhibitoraktivität
DK1495002T3 (da) Benzamide derivatives useful as histone deacetylase inhibitors
ATE473005T1 (de) Histone-deacetylase-inhibitoren
ATE354366T1 (de) Histondeacetylase-hemmer
EE200100373A (et) Bensoheterotsüklid ja nende kasutamine MEK inhibiitoritena
CY2015053I2 (el) Υδροξαμικα παραγωγα χρησιμα ως αναστολεις δεακετυλασης
NO20012245L (no) Anthranilsyreamider og anvendelse derav som medikamenter
NO20012688D0 (no) Benzamidderivater og anvendelse derav som APOB-100 sekresjonsinhibitorer
PT2860174T (pt) Derivado de benzamida como inibidor de histona desacetilase com diferenciação potente e atividade de antiproliferação
NO20020383L (no) Mutilinderivater og deres anvendelse som anti-bakterielle midler
AU2003219595A8 (en) Alpha,beta-unsaturated hydroxamic acid derivatives and their use as histone deacetylase inhibitors
PL374970A1 (en) Substituted thienyl-hydroxamic acids as histone deacetylase inhibitors
DK1040094T3 (da) Substitueret cyklopentan og cyklopenten-forbindelser anvendelige som neuraminidase-inhibitorer
FI19992171A7 (fi) Sprinkleri
AU2003286249A8 (en) Histone deacetylase inhibitors
DE60031633D1 (de) Wirkstofffreisetzendes elastisches band
PT864559E (pt) Compostos amino substituidos e sua utilizacao como substancias activas analgesicas
NO981178L (no) Vannl°selige korrosjonsinhibitorer
NO20032183D0 (no) Histon-deacetylase inhibitor og anvendelse derav
ATE455754T1 (de) Arylsulfonamid-substituierte hydroxamsäure- derivate
EP1408946A4 (de) Histondeacetylaseinhibitoren
AU2002330850A1 (en) Use of inhibitors of the abc drug transporter to increase the activity of anti-microbial agents
NO20020326L (no) Sammensetning og anvendelse av en inhibitor av PPAR-delta-aktivitet
ATE228122T1 (de) Umgekehrt hydroxamat inhibitoren von matrix metalloproteinasen
DK1301184T3 (da) Valproinsyre og derivater deraf som histondeacetylaseinhibitorer

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1208086

Country of ref document: EP

EEFA Change of the company name